clov-20220331
0001801170FALSE12-31Q12022CLOVER HEALTH INVESTMENTS, CORP. /DEP4Y00018011702022-01-012022-03-310001801170us-gaap:CommonClassAMember2022-05-02xbrli:shares0001801170us-gaap:CommonClassBMember2022-05-0200018011702022-03-31iso4217:USD00018011702021-12-310001801170us-gaap:CommonClassAMember2022-03-31iso4217:USDxbrli:shares0001801170us-gaap:CommonClassAMember2021-12-310001801170us-gaap:CommonClassBMember2022-03-310001801170us-gaap:CommonClassBMember2021-12-3100018011702021-01-012021-03-3100018011702020-12-310001801170us-gaap:CommonStockMember2020-12-310001801170us-gaap:TreasuryStockMember2020-12-310001801170us-gaap:AdditionalPaidInCapitalMember2020-12-310001801170us-gaap:RetainedEarningsMember2020-12-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2020-12-310001801170us-gaap:NoncontrollingInterestMember2020-12-310001801170us-gaap:CommonStockMember2021-01-012021-03-310001801170us-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-01-012021-03-310001801170us-gaap:CommonStockMemberclov:LegacyWarrantsMember2021-01-012021-03-310001801170clov:LegacyWarrantsMemberus-gaap:AdditionalPaidInCapitalMember2021-01-012021-03-310001801170clov:LegacyWarrantsMember2021-01-012021-03-310001801170us-gaap:RetainedEarningsMember2021-01-012021-03-3100018011702021-03-310001801170us-gaap:CommonStockMember2021-03-310001801170us-gaap:TreasuryStockMember2021-03-310001801170us-gaap:AdditionalPaidInCapitalMember2021-03-310001801170us-gaap:RetainedEarningsMember2021-03-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-03-310001801170us-gaap:NoncontrollingInterestMember2021-03-310001801170us-gaap:CommonStockMember2021-12-310001801170us-gaap:TreasuryStockMember2021-12-310001801170us-gaap:AdditionalPaidInCapitalMember2021-12-310001801170us-gaap:RetainedEarningsMember2021-12-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310001801170us-gaap:NoncontrollingInterestMember2021-12-310001801170us-gaap:CommonStockMember2022-01-012022-03-310001801170us-gaap:AdditionalPaidInCapitalMember2022-01-012022-03-310001801170us-gaap:RestrictedStockUnitsRSUMemberus-gaap:CommonStockMember2022-01-012022-03-310001801170us-gaap:CommonStockMemberclov:PerformanceRestrictedStockUnitsMember2022-01-012022-03-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-03-310001801170us-gaap:TreasuryStockMember2022-01-012022-03-310001801170us-gaap:NoncontrollingInterestMember2022-01-012022-03-310001801170us-gaap:RetainedEarningsMember2022-01-012022-03-310001801170us-gaap:CommonStockMember2022-03-310001801170us-gaap:TreasuryStockMember2022-03-310001801170us-gaap:AdditionalPaidInCapitalMember2022-03-310001801170us-gaap:RetainedEarningsMember2022-03-310001801170us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-03-310001801170us-gaap:NoncontrollingInterestMember2022-03-31xbrli:pureclov:Reportable_segment0001801170us-gaap:GeneralAndAdministrativeExpenseMember2022-01-012022-03-310001801170us-gaap:GeneralAndAdministrativeExpenseMember2021-01-012021-06-300001801170us-gaap:CashAndCashEquivalentsMember2022-01-012022-03-310001801170us-gaap:CashAndCashEquivalentsMember2021-01-012021-03-310001801170us-gaap:ShortTermInvestmentsMember2022-01-012022-03-310001801170us-gaap:ShortTermInvestmentsMember2021-01-012021-03-310001801170us-gaap:SecuritiesInvestmentMember2022-01-012022-03-310001801170us-gaap:SecuritiesInvestmentMember2021-01-012021-03-310001801170us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-03-31clov:position0001801170us-gaap:USGovernmentAgenciesDebtSecuritiesMember2021-12-310001801170us-gaap:FairValueInputsLevel1Member2022-03-310001801170us-gaap:FairValueInputsLevel2Member2022-03-310001801170us-gaap:FairValueInputsLevel3Member2022-03-310001801170us-gaap:FairValueInputsLevel1Member2021-12-310001801170us-gaap:FairValueInputsLevel2Member2021-12-310001801170us-gaap:FairValueInputsLevel3Member2021-12-310001801170us-gaap:FairValueInputsLevel3Memberclov:ConvertibleSecuritiesMember2020-12-310001801170us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2020-12-310001801170us-gaap:FairValueInputsLevel3Memberclov:WarrantsPayableMember2020-12-310001801170us-gaap:FairValueInputsLevel3Member2020-12-310001801170us-gaap:FairValueInputsLevel3Memberclov:ConvertibleSecuritiesMember2021-01-012021-03-310001801170us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-01-012021-03-310001801170us-gaap:FairValueInputsLevel3Memberclov:WarrantsPayableMember2021-01-012021-03-310001801170us-gaap:FairValueInputsLevel3Member2021-01-012021-03-310001801170us-gaap:FairValueInputsLevel3Memberclov:ConvertibleSecuritiesMember2021-03-310001801170us-gaap:FairValueInputsLevel3Memberus-gaap:DerivativeFinancialInstrumentsLiabilitiesMember2021-03-310001801170us-gaap:FairValueInputsLevel3Memberclov:WarrantsPayableMember2021-03-310001801170us-gaap:FairValueInputsLevel3Member2021-03-310001801170us-gaap:FairValueInputsLevel3Memberclov:SeekConvertibleNoteMember2020-09-250001801170us-gaap:FairValueInputsLevel3Memberclov:SeekConvertibleNoteMember2022-03-310001801170us-gaap:FairValueInputsLevel3Memberclov:SeekConvertibleNoteMember2021-12-310001801170us-gaap:FairValueInputsLevel3Member2022-01-012022-03-3100018011702021-09-090001801170clov:CarePointHealthContractMember2022-01-012022-03-310001801170clov:CarePointHealthContractMember2021-01-012021-03-310001801170clov:CarePointHealthContractMember2022-03-310001801170clov:CarePointHealthContractMember2021-12-310001801170clov:RogueTradingMember2022-01-012022-03-310001801170clov:RogueTradingMember2021-01-012021-03-310001801170clov:MedicalRecordsExchangeLLCMember2022-01-012022-03-310001801170clov:MedicalRecordsExchangeLLCMember2021-01-012021-03-310001801170clov:ThymeCareIncMember2022-01-012022-03-310001801170clov:NonInsuranceOperationsMember2022-03-310001801170clov:InsuranceOperationsMember2022-03-310001801170us-gaap:ConvertibleDebtMemberclov:SeekInsuranceServicesMember2020-09-250001801170us-gaap:ConvertibleDebtMemberclov:SeekInsuranceServicesMember2022-03-310001801170us-gaap:ConvertibleDebtMemberclov:SeekInsuranceServicesMember2021-12-310001801170us-gaap:ConvertibleDebtMemberclov:SeekInsuranceServicesMember2021-01-012021-03-310001801170us-gaap:ConvertibleDebtMemberclov:SeekInsuranceServicesMember2022-01-012022-03-310001801170us-gaap:LetterOfCreditMember2018-04-190001801170us-gaap:LetterOfCreditMember2018-04-192018-04-190001801170us-gaap:UnusedLinesOfCreditMemberus-gaap:LetterOfCreditMember2022-03-310001801170us-gaap:UnusedLinesOfCreditMemberus-gaap:LetterOfCreditMember2021-12-310001801170us-gaap:CommonClassBMember2022-01-012022-03-31clov:vote0001801170us-gaap:CommonClassAMember2022-01-012022-03-310001801170clov:PublicStockOfferingMember2021-11-012021-11-300001801170clov:PublicStockOfferingMember2021-11-300001801170us-gaap:CommonClassBMember2021-01-072021-01-070001801170clov:PrivateCapitalTransactionMemberclov:CloverTherapeuticsCompanyMemberus-gaap:PreferredStockMember2022-02-042022-02-040001801170clov:PrivateCapitalTransactionMemberclov:CloverTherapeuticsCompanyMember2022-02-040001801170us-gaap:CommonStockMemberclov:CloverTherapeuticsCompanyMember2022-02-040001801170us-gaap:OtherAssetsMemberclov:CloverTherapeuticsCompanyMemberus-gaap:PreferredStockMember2022-02-040001801170clov:CloverTherapeuticsCompanyMember2022-01-012022-03-310001801170clov:TwoThousandTwentyEquityAndManagementIncentivePlanMember2022-03-310001801170us-gaap:CommonClassAMemberclov:InducementPlanMember2022-03-090001801170clov:TwoThousandFourteenEquityIncentivePlanMember2022-03-310001801170clov:TwoThousandsTwentyEquityIncentivePlanMember2022-03-310001801170clov:TwoThousandsTwentyManagementIncentivePlanMember2022-03-310001801170clov:InducementPlanMember2022-03-310001801170clov:TwoThousandFourteenEquityIncentivePlanMember2021-12-310001801170clov:TwoThousandsTwentyEquityIncentivePlanMember2021-12-310001801170clov:TwoThousandsTwentyManagementIncentivePlanMember2021-12-310001801170us-gaap:EmployeeStockOptionMemberclov:TwoThousandFourteenEquityIncentivePlanMember2022-01-012022-03-310001801170us-gaap:ShareBasedCompensationAwardTrancheOneMemberus-gaap:EmployeeStockOptionMemberclov:TwoThousandFourteenEquityIncentivePlanMember2022-01-012022-03-310001801170us-gaap:ShareBasedCompensationAwardTrancheTwoMemberus-gaap:EmployeeStockOptionMemberclov:TwoThousandFourteenEquityIncentivePlanMember2022-01-012022-03-310001801170us-gaap:RestrictedStockUnitsRSUMemberclov:TwoThousandFourteenEquityIncentivePlanMember2022-01-012022-03-310001801170us-gaap:EmployeeStockOptionMember2022-01-012022-03-310001801170us-gaap:EmployeeStockOptionMember2021-01-012021-03-310001801170us-gaap:RestrictedStockUnitsRSUMember2022-01-012022-03-310001801170us-gaap:RestrictedStockUnitsRSUMember2021-01-012021-03-310001801170clov:PerformanceRestrictedStockUnitsMember2022-01-012022-03-310001801170clov:PerformanceRestrictedStockUnitsMember2021-01-012021-03-310001801170us-gaap:EmployeeStockMember2022-01-012022-03-310001801170us-gaap:EmployeeStockMember2021-01-012021-03-310001801170clov:TwoThousandsTwentyEquityIncentivePlanMember2022-01-012022-03-310001801170clov:TwoThousandFourteenEquityIncentivePlanMember2022-01-012022-03-310001801170clov:TwoThousandFourteenEquityIncentivePlanMember2021-01-012021-03-310001801170us-gaap:RestrictedStockUnitsRSUMember2020-12-310001801170us-gaap:RestrictedStockUnitsRSUMember2021-03-310001801170us-gaap:RestrictedStockUnitsRSUMember2021-12-310001801170us-gaap:RestrictedStockUnitsRSUMember2022-03-310001801170clov:PerformanceRestrictedStockUnitsMember2020-12-310001801170clov:PerformanceRestrictedStockUnitsMember2021-03-310001801170clov:PerformanceRestrictedStockUnitsMember2021-12-310001801170clov:PerformanceRestrictedStockUnitsMember2022-03-310001801170us-gaap:CommonClassAMemberus-gaap:EmployeeStockMember2021-01-062021-01-060001801170us-gaap:EmployeeStockMember2021-01-060001801170us-gaap:EmployeeStockMember2021-01-062021-01-060001801170us-gaap:CommonClassAMemberus-gaap:EmployeeStockMember2022-03-310001801170us-gaap:EmployeeStockMemberus-gaap:SubsequentEventMember2022-05-090001801170srt:WeightedAverageMemberus-gaap:EmployeeStockMember2022-01-012022-03-3100018011702016-11-3000018011702017-12-310001801170clov:OptionsToPurchaseCommonStockMember2022-01-012022-03-310001801170clov:OptionsToPurchaseCommonStockMember2021-01-012021-03-310001801170clov:WarrantsToPurchaseCommonStockMember2022-01-012022-03-310001801170clov:WarrantsToPurchaseCommonStockMember2021-01-012021-03-31clov:segment0001801170clov:InsuranceMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001801170clov:NonInsuranceMemberus-gaap:OperatingSegmentsMember2022-01-012022-03-310001801170us-gaap:CorporateNonSegmentMember2022-01-012022-03-310001801170us-gaap:IntersegmentEliminationMember2022-01-012022-03-310001801170clov:InsuranceMemberus-gaap:OperatingSegmentsMember2022-03-310001801170clov:NonInsuranceMemberus-gaap:OperatingSegmentsMember2022-03-310001801170us-gaap:CorporateNonSegmentMember2022-03-310001801170us-gaap:IntersegmentEliminationMember2022-03-31

I I 😀🚩🚩2w
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
________________________________________
FORM 10-Q
________________________________________
(Mark One)
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2022
OR
oTRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
For the transition period from ________ to ________
Commission File Number: 001-39252
________________________________________
Clover Health Investments, Corp.
(Exact Name of Registrant as Specified in its Charter)
________________________________________
Delaware98-1515192
(State or other jurisdiction of
incorporation or organization)
(I.R.S. Employer
Identification No.)
3401 Mallory Lane, Suite 210
Franklin, Tennessee
37067
(Address of principal executive offices)(Zip Code)
Registrant’s telephone number, including area code: (201) 432-2133
________________________________________
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading
Symbol(s)
Name of each exchange on which registered
Class A Common Stock, par value $0.0001 per shareCLOVThe NASDAQ Stock Market LLC
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.     Yes  x    No  o
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).     Yes  x    No  o
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.
Large accelerated filer
x
Accelerated filero
Non-accelerated fileroSmaller reporting companyo
Emerging growth companyo
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).     Yes  o    No  x
As of May 2, 2022, the registrant had 378,916,307 shares of Class A Common Stock, $0.0001 par value per share, and 94,446,449 shares of Class B Common Stock, $0.0001 par value per share, issued and outstanding.


1


Table of Contents
Page


2



As used in this report, "Company," "Clover," "Clover Health," "we," "us," "our," and similar terms refer to Clover Health Investments, Corp. and its consolidated subsidiaries, unless otherwise noted or the context otherwise requires.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This document contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). All statements contained in this document other than statements of historical fact, including statements regarding our future results of operations, financial position, market size and opportunity, our business strategy and plans, the factors affecting our performance and our objectives for future operations, are forward-looking statements. The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "could," "should," “would," "can," "expect," "project," "outlook," "forecast," "objective," "plan," "potential," "seek," "grow," "target," "if," and the negative or plural of these words and similar expressions are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and trends that we believe may affect our financial condition, results of operations, business strategy, short-term and long-term business operations and objectives and financial needs. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including the risk factors described in our filings with the Securities and Exchange Commission (the "SEC"). Moreover, we operate in a very competitive and rapidly changing environment. New risks emerge from time to time. It is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements we may make. In light of these risks, uncertainties and assumptions, the future events and trends discussed in this document may not occur, and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. Forward-looking statements contained in this document involve a number of judgments, risks and uncertainties, including, without limitation, risks related to:

our expectations regarding results of operations, financial condition, and cash flows;
our expectations regarding the development and expansion of our Insurance and Non-Insurance businesses;
our ability to successfully enter new service markets and manage our operations;
anticipated trends and challenges in our business and in the markets in which we operate;
our ability to expand our beneficiary base and provider network;
our ability to maintain and increase adoption and use of the Clover Assistant;
the anticipated benefits associated with the use of the Clover Assistant platform, including our ability to utilize the platform to manage our medical care ratios;
our ability to develop new features and functionality that meet market needs and achieve market acceptance;
our ability to retain and hire necessary employees and staff our operations appropriately;
the timing and amount of certain investments in growth;
the effect of uncertainties related to the global COVID-19 pandemic on our business, results of operations, and financial condition;
the outcome of any known and unknown litigation and regulatory proceedings;
any current, pending, or future legislation, regulations or policies that could have a negative effect on our revenue and businesses, including rules, regulations, and policies relating to healthcare and Medicare;
our ability to maintain or improve our Star Ratings or otherwise continue to improve the financial performance of our business;
our ability to maintain, protect, and enhance our intellectual property; and
general economic conditions, including the societal and economic impact of the COVID-19 pandemic and its variants, and geopolitical uncertainty and instability.

We caution you that the foregoing list of judgments, risks, and uncertainties that may cause actual results to differ materially from those in the forward-looking statements may not be complete. You should not rely upon forward-looking statements as predictions of future events. The events and circumstances reflected in the forward-looking statements may not be achieved or occur or may be materially different from what we expect. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance, or achievements. Except as required by law, we undertake no obligation to update any of these forward-looking statements after the date of this document or to conform these statements to actual results or revised expectations.

This document contains estimates, projections, and other information concerning our industry, our business, and the markets for our products. We obtained the industry, market, and similar data set forth in this document from our own internal estimates and research and from industry research, publications, surveys, and studies conducted by third parties, including governmental agencies, and such information is inherently subject to uncertainties. Actual events or circumstances may differ materially from events and circumstances that are assumed in this information. You are cautioned not to give undue weight to any such information, projections, or estimates.

3


As a result of a number of known and unknown risks and uncertainties, including without limitation, the important factors described in our reports filed with the SEC, including the discussion under "Risk Factors" in our Annual Report on Form 10-K for the year ended December 31, 2021, as filed with the SEC and available on its website at www.sec.gov, our actual results or performance may be materially different from those expressed or implied by these forward-looking statements.

Additional Information

Our website address is www.cloverhealth.com. Our filings with the SEC are posted on our website and available free of charge as soon as reasonably practical after they are electronically filed with, or furnished to, the SEC. The SEC's website, www.sec.gov, contains reports, proxy statements and other information regarding issuers that file electronically with the SEC. The content on our website or on any other website referred to in this document is not incorporated by reference in this document. Further, the Company's references to website URLs are intended to be inactive textual references only.

Channels for Disclosure of Information

Investors and others should note that we routinely announce material information to investors and the marketplace using filings with the SEC, press releases, public conference calls, presentations, webcasts, and the investor relations page of our website. We use the investor relations page of our website for purposes of compliance with Regulation FD and as a routine channel for distribution of important information, including news releases, analyst presentations, financial information, and corporate governance practices. We also intend to use certain social media channels as a means of disclosing information about the Company and our products to our customers, investors, and the public, including @CloverHealth and #CloverHealth on Twitter, and the LinkedIn account of our President, Andrew Toy. The information posted on social media channels is not incorporated by reference in this report or in any other report or document we file with the SEC. While not all of the information that we post to the investor relations page of our website or to social media accounts is of a material nature, some information could be deemed to be material. Accordingly, we encourage investors, the media, and others interested in the Company to review the information that we share at the "Investors" link located at the bottom of our webpage at https://investors.cloverhealth.com/investor-relations and to sign up for and regularly follow our social media accounts. Users may automatically receive email alerts and other information about the Company when enrolling an email address by visiting "Email Alerts" in the "Investor Resources" section of our website at https://investors.cloverhealth.com/investor-relations.

Operating Segments

We have updated the names of our Medicare Advantage and Direct Contracting segments to the Insurance and Non-Insurance segments, respectively. We believe that this approach better reflects each segment’s current role and contribution to its business. There has been no change to the existing composition of these segments, and previously reported consolidated and segment-level financial results of the Company were not impacted by these changes. Defined terms and metrics in this report reflect the new segment names.
4



Part I
Item 1. Financial Statements and Supplementary Data

CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share amounts)


March 31, 2022
(Unaudited)
December 31, 2021
Assets
Current assets
Cash and cash equivalents$273,831 $299,968 
Short-term investments212,258 293,851 
Investment securities, available-for sale (Amortized cost: 2022: $77,855; 2021: $21,142)
77,401 21,131 
Investment securities, held-to-maturity (Fair value: 2022: $306; 2021: $307)
305 305 
Accrued retrospective premiums57,681 34,923 
Other receivables13,731 14,282 
Healthcare receivable42,179 48,042 
Non-Insurance performance year receivable1,760,144  
Surety bonds and deposits14,769 12,613 
Prepaid expenses21,937 9,409 
Other assets, current17,181 18,022 
Total current assets2,491,417 752,546 
Investment securities, available-for sale (Amortized cost: 2022: $165,503; 2021: $177,527)
158,699 175,604 
Investment securities, held-to-maturity (Fair value: 2022: $367; 2021: $364)
350 335 
Equity method investment3,177  
Property and equipment, net2,311 2,287 
Operating lease right-of-use assets5,000 5,367 
Goodwill and other intangible assets4,233 4,233 
Other assets, non-current14,707 10,432 
Total assets$2,679,894 $950,804 


The accompanying notes are an integral part of these condensed consolidated financial statements.



5


CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Dollars in thousands, except share amounts)


March 31, 2022
(Unaudited)
December 31, 2021
Liabilities and Stockholders' Equity
Current liabilities
Unpaid claims$164,240 $138,604 
Due to related parties, net1,950 2,320 
Non-Insurance performance year obligation, current1,780,297 36,891 
Non-Insurance payable81,003 37,773 
Accounts payable and accrued expenses27,451 28,129 
Accrued salaries and benefits11,590 15,147 
Operating lease liabilities2,411 3,059 
Premium deficiency reserve82,971 110,628 
Other liabilities, current110 73 
Total current liabilities2,152,023 372,624 
Notes and securities payable, net of discounts and deferred issuance costs19,947 19,938 
Long-term operating lease liabilities4,947 4,830 
Other liabilities, non-current13,164 14,095 
Total liabilities2,190,081 411,487 
Commitments and Contingencies (Note 15)
Stockholders' equity
Class A Common Stock, $0.0001 par value; 2,500,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 378,854,310 and 352,645,626 issued and outstanding as of March 31, 2022, and December 31, 2021, respectively
37 34 
Class B Common Stock, $0.0001 par value; 500,000,000 shares authorized as of March 31, 2022, and December 31, 2021; 94,448,208 and 118,206,768 issued and outstanding as of March 31, 2022, and December 31, 2021, respectively
9 12 
Additional paid-in capital2,195,158 2,154,187 
Accumulated other comprehensive loss(7,258)(1,934)
Accumulated deficit(1,692,047)(1,616,738)
Less: Treasury stock, at cost; 1,893,793 and 14,730 shares held as of March 31, 2022, and December 31, 2021, respectively
(6,086)(147)
Clover stockholders' equity489,813 535,414 
Noncontrolling interest 3,903 
Total stockholders' equity489,813 539,317 
Total liabilities and stockholders' equity$2,679,894 $950,804 


The accompanying notes are an integral part of these condensed consolidated financial statements.


6


CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS (Unaudited)
(Dollars in thousands, except per share and share amounts)
Three Months Ended March 31,
20222021
Revenues:
Premiums earned, net (Net of ceded premiums of $119 and $124 for the three months ended March 31, 2022 and 2021, respectively)
$278,169 $199,376 
Non-Insurance revenue594,898  
Other income1,312 949 
Total revenues874,379 200,325 
Operating expenses:
Net medical claims incurred861,722 214,420 
Salaries and benefits69,091 66,024 
General and administrative expenses57,697 38,618 
Premium deficiency reserve benefit(27,657) 
Depreciation and amortization826 160 
Other expense 191 
Total operating expenses961,679 319,413 
Loss from operations(87,300)(119,088)
Change in fair value of warrants payable (85,506)
Interest expense403 1,175 
Amortization of notes and securities discounts 13,660 
Gain on investment(12,394) 
Net loss$(75,309)$(48,417)
Per share data:
Net loss per share attributable to Class A and Class B common stockholders – basic and diluted (1)
$(0.16)$(0.13)
Weighted average number of common shares outstanding
Basic and diluted weighted average number of Class A and Class B common shares and common share equivalents outstanding (1)
473,028,651 376,170,545 
Net unrealized loss on available-for-sale investments$(5,324)$(493)
Comprehensive loss$(80,633)$(48,910)
(1) Because the Company had a net loss during the three months ended March 31, 2022 and 2021, the Company's potentially dilutive securities, which include stock options, restricted stock, preferred stock, and warrants to purchase shares of common stock and preferred stock, have been excluded from the computation of diluted net loss per share, as the effect would be anti-dilutive.
The accompanying notes are an integral part of these condensed consolidated financial statements.
7


CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN CONVERTIBLE PREFERRED STOCK AND STOCKHOLDERS' EQUITY (Unaudited)
(Dollars in thousands, except share amounts)
Convertible Preferred stockClass A and Class B Common StockTreasury StockAdditional paid-in capitalAccumulated
deficit
Accumulated
other
comprehensive
income (loss)
Noncontrolling
interest
Total stockholders' equity (deficit)
Shares
AmountSharesAmount
Shares
Amount
Balance, December 31, 2020
139,444,346 $447,747 89,206,266 $9  $ $411,867 $(1,028,982)$10 $3,903 $(613,193)
Stock issuance for exercise of stock options, net of early exercise liability— — 761,480 — — — 1,282 — — — 1,282 
Stock-based compensation— — — — — — 42,713 — — — 42,713 
Unrealized holdings loss on investment securities, available-for-sale— — — — — — — — (493)— (493)
Preferred stock conversion(139,444,346)(447,747)139,444,346 14 — — 447,733 — — — 447,747 
Issuance of common stock related to exercises of legacy warrants— — 7,205,490 1 — — 97,781 — — — 97,782 
Convertible debt conversion and other issuances— — 75,084,703 7 — — 16,052 — — — 16,059 
Issuance of common stock in connection with Business Combination and PIPE offering— — 96,398,800 15 — — 666,232 — — — 666,247 
Capital contribution for extinguishment of debt— — — — — — 126,795 — — — 126,795 
Acquisition of Public and Private Placement Warrants— — — — — — (147,582)— — — (147,582)
Net loss— — — — — — — (48,417)— — (48,417)
Balance, March 31, 2021
 $ 408,101,085 $46  $ $1,662,873 $(1,077,399)$(483)$3,903 $588,940 
Balance, December 31, 2021
 $ 470,852,394 $46 14,730 $(147)$2,154,187 $(1,616,738)$(1,934)$3,903 $539,317 
Stock issuance for exercise of stock options, net of early exercise liability— — 151,620 — — — 331 — — — 331 
Stock-based compensation— — — — — — 40,640 — — — 40,640 
Vested restricted stock units— — 2,074,756 — — — — — — — — 
Vested performance restricted stock units— — 8,951 — — — — — — — — 
Unrealized holdings loss on investment securities, available-for-sale— — — — — — — — (5,324)— (5,324)
Treasury stock acquired— — — — 1,879,063 (5,939)— — — — (5,939)
Issuance of common stock under Employee Stock Purchase Plan— — 214,797 — — — — — — — — 
Derecognition of noncontrolling interest— — — — — — — — — (3,903)(3,903)
Net loss— — — — — — — (75,309)— — (75,309)
Balance, March 31, 2022
 $ 473,302,518 $46 1,893,793 $(6,086)$2,195,158 $(1,692,047)$(7,258)$ $489,813 
The accompanying notes are an integral part of these condensed consolidated financial statements.
8


CLOVER HEALTH INVESTMENTS, CORP.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Unaudited)
(Dollars in thousands)
Three Months Ended March 31,
20222021
Cash flows from operating activities:
Net loss$(75,309)$(48,417)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization expense826 160 
Amortization of notes and securities discounts and debt issuance costs 13,660 
Stock-based compensation expense40,640 42,713 
Change in fair value of warrants payable and amortization of warrants (85,506)
Accretion, net of amortization(17)52 
Net realized losses on investment securities 61 
Gain on investment(12,394) 
Premium deficiency reserve(27,657) 
Changes in operating assets and liabilities:
Accrued retrospective premiums(22,758)(19,350)
Other receivables551 (7,843)
Performance year receivable(16,738) 
Surety bonds and deposits(2,156) 
Prepaid expenses(12,528)(6,294)
Other assets1,432 (6,622)
Healthcare receivables5,863 8,520 
Operating lease right-of-use assets1,015 881 
Unpaid claims25,266 13,606 
Accounts payable and accrued expenses(678)(4,502)
Accrued salaries and benefits(3,557)6,874 
Other liabilities(894)151 
Non-Insurance payable43,230  
Operating lease liabilities(1,179)(1,013)
Net cash used in operating activities(57,042)(92,869)
Cash flows from investing activities:
Purchases of short-term investments, available-for-sale, and held-to-maturity securities(113,079)(274,909)
Proceeds from sales of short-term investments and available-for-sale securities 17,267 
Proceeds from maturities of short-term investments and available-for-sale securities150,000 265 
Purchases of property and equipment(158)(99)
Acquisition of Clover Therapeutics Series A preferred shares(250) 
Net cash provided by (used in) investing activities36,513 (257,476)
Cash flows from financing activities:
Payment of notes payable principal (5,020)
Issuance of common stock, net of early exercise liability331 1,282 
Proceeds from reverse recapitalization, net of transaction costs 666,242 
Treasury stock acquired(5,939) 
Net cash (used in) provided by financing activities(5,608)662,504 
Net (decrease) increase in cash and cash equivalents(26,137)312,159 
Cash and cash equivalents, beginning of period299,968 92,348 
Cash and cash equivalents, end of period$273,831 $404,507 
Supplemental cash flow disclosures
Cash paid during the period for interest$ $812 
Supplemental disclosure of non-cash activities
Performance year receivable$(1,743,406)$ 
Performance year obligation1,743,406  
Conversion of preferred stock to common stock 447,747 
Issuance of common stock related to convertible debt 16,059 
Capital contribution for extinguishment of debt 126,795 
Issuance of common stock related to warrants exercised 97,782 
Acquisition of Public and Private Warrants 147,582 
Right-of-use assets obtained in exchange for lease liabilities648 101 
Recognition of equity method investments and preferred stock8,644  
Derecognition of noncontrolling interest3,903  
Conversion of Clover Therapeutics convertible note to preferred stock250  
The accompanying notes are an integral part of these consolidated financial statements.
9


CLOVER HEALTH INVESTMENTS, CORP. AND SUBSIDIARIES
Notes to Unaudited Condensed Consolidated Financial Statements
1. Organization and Operations
Clover Health Investments, Corp. (collectively with its affiliates and subsidiaries, "Clover" or the "Company") is singularly focused on creating great, sustainable healthcare to improve every life. Clover has centered its strategy on building and deploying technology through its flagship software platform, the Clover Assistant, to help America’s seniors receive better care at lower costs.
Clover provides affordable, high-quality Medicare Advantage (MA) plans, including Preferred Provider Organization (PPO) and Health Maintenance Organization (HMO) plans, through its regulated insurance subsidiaries. The Company's regulated insurance subsidiaries consist of Clover Insurance Company and Clover HMO of New Jersey Inc., which operate the Company's PPO and HMO health plans, respectively. On April 1, 2021, the Company's subsidiary, Clover Health Partners, LLC, began participating as a Direct Contracting Entity (DCE) in the Global and Professional Direct Contracting Model (DC Model) of the Centers for Medicare and Medicaid Services (CMS), an agency of the United States Department of Health and Human Services, through which the Company provides care to aligned Original Medicare beneficiaries (the "Non-Insurance Beneficiaries"). Medical Service Professionals of NJ, LLC, houses Clover's employed physicians and the related support staff for Clover's in-home care program. Clover's administrative functions and insurance operations are primarily operated by its Clover Health, LLC and Clover Health Labs, LLC subsidiaries.
Clover's approach is to combine technology, data analytics, and preventive care to lower costs and increase the quality of health and life of Medicare beneficiaries. Clover's technology platform uses machine learning-powered systems to deliver data and insights to physicians at the point of care in order to improve outcomes for beneficiaries and drive down costs. Clover's MA plans generally provide access to a wide network of primary care providers, specialists, and hospitals, enabling its members to see any doctor participating in Medicare willing to accept them. Clover focuses on minimizing members' out-of-pocket costs and offers many plans that allow members to pay the same co-pays for primary care provider visits regardless of whether their physician is in- or out-of-network. Through its Non-Insurance operations, which the Company previously referred to as its Direct Contracting operations, the Company assumes full risk (i.e., 100.0% shared savings and shared losses) for the total cost of care of aligned Non-Insurance Beneficiaries, empowers providers with the Clover Assistant, and offers a variety of programs aimed at reducing expenditures and preserving or enhancing the quality of care for Non-Insurance Beneficiaries. For additional information related to the Company's Non-Insurance operations, see Note 16 in this report.
Clover was originally incorporated as a Cayman Islands exempted company on October 18, 2019, as a special purpose acquisition company under the name Social Capital Hedosophia Holdings Corp. III (SCH). On October 5, 2020, SCH entered into a Merger Agreement (the "Merger Agreement") with Clover Health Investments, Corp., a corporation originally incorporated on July 17, 2014, in the state of Delaware (Legacy Clover). Pursuant to the Merger Agreement, and a favorable vote of SCH's stockholders at an extraordinary general meeting on January 6, 2021 (the "Special Meeting"), on January 7, 2021, Asclepius Merger Sub Inc., a Delaware corporation and a newly formed, wholly-owned subsidiary of SCH (Merger Sub), merged with and into Legacy Clover. The separate corporate existence of Merger Sub ceased, Legacy Clover survived and merged with and into SCH, with SCH as the surviving corporation, and SCH was redomesticated as a Delaware corporation and renamed Clover Health Investments, Corp. (the "Business Combination"). The Business Combination was accounted for as a reverse recapitalization in accordance with generally accepted accounting principles in the United States (GAAP). Under the guidance in Accounting Standards Codification (ASC) 805, Legacy Clover is treated as the "acquirer" for financial reporting purposes, Legacy Clover is deemed the accounting predecessor of the combined business, and Clover Health Investments, Corp., as the parent company of the combined business, is the successor Securities and Exchange Commission (SEC) registrant, meaning that Legacy Clover's financial statements for previous periods are disclosed in periodic reports filed with the SEC.
The Business Combination has had and will have a significant impact on the Company's future reported financial position and results as a consequence of the reverse recapitalization. The Business Combination closed on January 7, 2021, and on the following day the Company's Class A Common Stock and then outstanding public warrants were listed on the Nasdaq Global Select Market (Nasdaq) under the symbols "CLOV" and "CLOVW," respectively, for trading in the public market.
For additional information, see Note 1 (Organization and Operations) and Note 3 (Business Combination) included in the Company's Annual Report on Form 10-K for the year ended December 31, 2021 (the "2021 Form 10-K").

10


2. Summary of Significant Accounting Policies
Basis of presentation
The Company's interim condensed consolidated financial statements have been prepared in conformity with GAAP and include the accounts of the Company and its wholly-owned subsidiaries. In the opinion of management, the Company has made all necessary adjustments, which include normal recurring adjustments necessary for a fair presentation of its financial position and its results of operations for the interim periods presented. All material intercompany balances and transactions have been eliminated in consolidating these financial statements. Investments over which we exercise significant influence, but do not control, are accounted for using the applicable accounting treatment based on the nature of the investment. These interim condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes to the financial statements included in the 2021 Form 10-K.
Use of estimates
The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that impact the amounts reported in the condensed consolidated financial statements and the accompanying notes.
The areas involving the most significant use of estimates are the amounts of incurred but not reported claims. Many factors can cause actual outcomes to deviate from these assumptions and estimates, such as changes in economic conditions, changes in government healthcare policy, advances in medical technology, changes in treatment patterns, and changes in average lifespan. Accordingly, the Company cannot determine with precision the ultimate amounts that it will pay for, or the timing of payment of actual claims, or whether the assets supporting the liabilities will grow to the level the Company assumes prior to payment of claims. If the Company's actual experience is different from its assumptions or estimates, the Company's reserves may prove inadequate. As a result, the Company would incur a charge to operations in the period in which it determines such a shortfall exists, which could have a material adverse effect on the Company's business, results of operations, and financial condition. Other areas involving significant estimates include risk adjustment provisions related to Medicare contracts and the valuation of the Company's investment securities, goodwill and other intangible assets, reinsurance, premium deficiency reserve, warrants, embedded derivative related to convertible securities, stock-based compensation, recoveries from third parties for coordination of benefits, Direct Contracting benchmark, specifically cost trend and risk score estimates that can develop over time, and final determination of medical cost adjustment pools.
Equity method of accounting and variable interest entities
Investments in entities in which the Company does not have control but its ownership falls between 20.0% and 50.0%, or it has the ability to exercise significant influence over operating and financial policies, are accounted for under the equity method of accounting.
The Company continuously assesses its partially-owned entities to determine if these entities are variable interest entities (VIEs) and, if so, whether the Company is the primary beneficiary and, therefore, required to consolidate the VIE. To make this determination, the Company applies a qualitative approach to determine whether the Company has both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb losses of, or the rights to receive benefits from, the VIE that could potentially be significant to that VIE. If the Company has an interest in a VIE but is determined to not be the primary beneficiary, the Company accounts for the interest under the equity method of accounting.
Segment information
Operating segments are defined as components of an enterprise for which separate financial information is available that is evaluated on a regular basis by the Chief Operating Decision Maker (CODM) in deciding how to allocate resources to an individual segment and in assessing performance. The Company's CODM is its Chief Executive Officer. The Company operates in two reporting segments: Insurance and Non-Insurance.
Performance guarantees
Certain of the Company's arrangements with third-party providers require it to guarantee the performance of its care network to CMS. As a result of the Company's participation in the DC Model, the Company determined that it was making a performance guarantee with respect to providers of Non-Insurance Beneficiaries that should be recognized in the financial statements. Accordingly, a liability for the performance guarantee was recorded on the Condensed Consolidated Balance Sheet. Each month, as the performance guarantee is fulfilled, the guarantee is amortized on a straight-line basis for the amount that represents the completed performance. With respect to each performance year in which the DCE is a participant, the final consideration due to the DCE from CMS (shared savings) or the consideration due to CMS from the DCE (shared loss) is reconciled in the subsequent years following the performance year. The shared savings or loss is measured periodically and will be applied to the Non-Insurance performance obligation if the
11


Company is in a probable loss position. The DCE has entered into a surety bond agreement with CMS and a third-party surety to cover the reserve requirement, which is fifty percent of the amount determined by the CMS agreement.
Capitalized software development costs - cloud computing arrangements
The Company's cloud computing arrangements mostly comprise hosting arrangements which are service contracts, whereby the Company gains remote access to use enterprise software hosted by the vendor or another third party on an as-needed basis for a period of time in exchange for a subscription fee. Implementation costs for cloud computing arrangements are capitalized if certain criteria are met and consist of internal and external costs directly attributable to developing and configuring cloud computing software for its intended use. These capitalized implementation costs are presented in the Condensed Consolidated Balance Sheets in other assets, and are generally amortized over the fixed, non-cancelable term of the associated hosting arrangement on a straight-line basis.
Deferred acquisition costs
Acquisition costs directly related to the successful acquisition of new business, which is primarily made up of commissions costs, are deferred and subsequently amortized. Deferred acquisition costs are recorded as other assets on the Condensed Consolidated Balance Sheet and are amortized over the estimated life of the related contracts. The amortization of deferred acquisition costs is recorded in general and administrative expenses in the Condensed Consolidated Statement of Operations and Comprehensive Loss. As of March 31, 2022, and December 31, 2021, there were no deferred acquisition costs as a result of the acceleration of amortization for deferred acquisition costs due to the recognition of a premium deficiency reserve. For the three months ended March 31, 2022 and 2021, charges related to deferred acquisition costs of $11.8 million and $1.8 million, respectively, were recognized in general and administrative expenses.
COVID-19
The societal and economic impact of the novel coronavirus (COVID-19) pandemic and its variants are continuing to evolve, and the ultimate impact on the Company's business, results of operations, financial condition, and cash flows is uncertain and difficult to predict. The global pandemic has severely impacted businesses worldwide, including many in the health insurance sector. In response to the pandemic, the Company has implemented additional steps related to its care delivery, member support, and internal policies and operations.
Recent accounting pronouncements
Recently adopted accounting pronouncements
Accounting for convertible instruments and contracts in an entity's own equity
In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity's Own Equity (Subtopic 815-40). The amendments in ASU 2020-06 simplify the accounting for convertible instruments by removing certain separation models for convertible instruments. Under the amendments in ASU 2020-06, the embedded conversion features no longer are separated from the host contract for convertible instruments with conversion features that are not required to be accounted for as derivatives, or that do not result in substantial premiums accounted for as paid-in capital. Consequently, a convertible debt instrument will be accounted for as a single liability measured at its amortized cost, and a convertible preferred stock will be accounted for as a single equity instrument measured at its historical cost, as long as no other features require bifurcation and recognition as derivatives. ASU 2020-06 is effective for nonpublic entities for fiscal years beginning after December 15, 2023. Early adoption is permitted, but no earlier than fiscal years beginning after December 15, 2020, and public entities beginning after December 15, 2021. The Company adopted this standard on January 1, 2022. The adoption of ASU 2020-06 did not have an impact on the Company's financial statements.
Accounting pronouncements effective in future periods

In August 2018, the FASB issued ASU 2018-12, Financial Services - Insurance (Topic 944): Targeted Improvements to the Accounting for Long-Duration Contracts, which was subsequently amended by ASU 2019-09, Financial Services—Insurance (Topic 944): Effective Date and ASU 2020-11, Financial Services—Insurance (Topic 944): Effective Date and Early Application. ASU 2020-11 was issued in consideration of the implications of COVID-19 and to provide transition relief and additional time for implementation by deferring the effective date by one year. The amendments in ASU 2018-12 make changes to a variety of areas to simplify or improve the existing recognition, measurement, presentation, and disclosure requirements for long-duration contracts issued by an insurance entity. The amendments require insurers to annually review the assumptions they make about their policyholders and update the liabilities for future policy benefits if the assumptions change. The amendments also simplify the amortization of deferred acquisition costs and add new disclosure requirements about the assumptions used to measure liabilities and
12


the potential impact to future cash flows. The amendments related to the liability for future policy benefits for traditional and limited-payment contracts and deferred acquisition costs are to be applied to contracts in force as of the beginning of the earliest period presented, with an option to apply such amendments retrospectively with a cumulative-effect adjustment to the opening balance of retained earnings as of the earliest period presented. The amendments for market risk benefits are to be applied retrospectively. ASU 2020-11 is effective for nonpublic entities and smaller reporting companies for fiscal years beginning after December 15, 2023, and for public entities beginning after December 15, 2022. The Company is currently evaluating the effects the adoption of ASU 2018-12 and ASU 2020-11 will have on its financial statements.

3. Investment Securities
The following tables present amortized cost and fair values of investments as of March 31, 2022, and December 31, 2021, respectively:
March 31, 2022Amortized costAccumulated unrealized gainsAccumulated unrealized lossesFair value
(in thousands)
Investment securities, held-to-maturity
U.S. government and government agencies and authorities
$655 $38 $(20)$673 
Investment securities, available-for-sale
U.S. government and government agencies and authorities
243,358 21 (7,279)236,100 
Total investment securities
$244,013 $59 $(7,299)$236,773 

December 31, 2021Amortized costAccumulated unrealized gainsAccumulated unrealized lossesFair value
(in thousands)
Investment securities, held-to-maturity
U.S. government and government agencies and authorities
$640 $40 $(9)$671 
Investment securities, available-for-sale
U.S. government and government agencies and authorities
198,669 10 (1,944)196,735 
Total investment securities
$199,309 $50 $(1,953)$197,406 
The following table presents the amortized cost and fair value of debt securities as of March 31, 2022, by contractual maturity:
March 31, 2022Held-to-maturityAvailable-for-sale
Amortized costFair valueAmortized costFair value
(in thousands)
Due within one year$305 $306 $77,855 $77,401 
Due after one year through five years30 30 160,539 154,180 
Due after five years through ten years210 190 4,964 4,519 
Due after ten years110 147   
Total$655 $673 $243,358 $236,100 
13


For the three months ended March 31, 2022 and 2021, respectively, net investment income, which is included within other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, was derived from the following sources:
Three Months Ended March 31,
20222021
(in thousands)
Cash and cash equivalents$2 $ 
Short-term investments71 37 
Investment securities237 47 
Investment income, net$310 $84 
Gross unrealized losses and fair values aggregated by investment category and length of time that individual securities have been in a continuous unrealized loss position were as follows at March 31, 2022, and December 31, 2021.
March 31, 2022Less than 12 monthsGreater than 12 monthsTotal
Fair valueUnrealized lossFair valueUnrealized lossFair valueUnrealized loss
(in thousands, except number of positions)
U.S. government and government agencies and authorities$189,934 $(5,033)$28,759 $(2,266)$218,693 $(7,299)
Total$189,934 $(5,033)$28,759 $(2,266)$218,693 $(7,299)
Number of positions21 6 27 
December 31, 2021Less than 12 monthsGreater than 12 monthsTotal
Fair valueUnrealized lossFair valueUnrealized lossFair valueUnrealized loss
(in thousands, except number of positions)
U.S. government and government agencies and authorities$187,251 $(1,555)$7,902 $(398)$195,153 $(1,953)
Total$187,251 $(1,555)$7,902 $(398)$195,153 $(1,953)
Number of positions18 4 22 
The Company did not record any credit allowances for debt securities that were in an unrealized loss position as of March 31, 2022, and December 31, 2021.
As of March 31, 2022, all securities were investment grade, with credit ratings of AA+ or higher by S&P. Unrealized losses on investment grade securities are principally related to changes in interest rates or changes in issuer or sector related credit spreads since the securities were acquired. The gross unrealized investment losses as of March 31, 2022, were assessed, based on, among other things:
The relative magnitude to which fair values of these securities have been below their amortized cost was not indicative of an impairment loss;
The absence of compelling evidence that would cause the Company to call into question the financial condition or near-term prospects of the issuer of the applicable security; and
The Company's ability and intent to hold the applicable security for a period of time sufficient to allow for any anticipated recovery.
14


Proceeds from sales and maturities of investment securities, inclusive of short-term investments, and related gross realized gains (losses) which are included within other income in the Condensed Consolidated Statements of Operations and Comprehensive Loss, were as follows for the three months ended March 31, 2022 and 2021, respectively:
Three Months Ended March 31,
20222021
(in thousands)
Proceeds from sales of investment securities$ $17,267 
Proceeds from maturities of investment securities150,000 265 
Gross realized gains 16 
Gross realized losses (77)
Net realized losses$ $(61)
As of March 31, 2022, and December 31, 2021, the Company had $11.2 million and $11.1 million, respectively, in deposits with various states and regulatory bodies that are included as part of the Company's investment balances.

4. Fair Value Measurements
The following table presents a summary of fair value measurements for financial instruments as of March 31, 2022, and December 31, 2021, respectively:
March 31, 2022Level 1Level 2Level 3
Total fair
value
(in thousands)
U.S. government and government agencies$ $236,100 $ $236,100 
Total assets at fair value$ $236,100 $ $236,100 
December 31, 2021Level 1Level 2Level 3
Total fair
value
(in thousands)
U.S. government and government agencies$ $196,735 $ $196,735 
Total assets at fair value$ $196,735 $ $196,735 
For additional information regarding the fair value measurements for financial instruments, see Note 5 (Fair Value Measurements) in the 2021 Form 10-K. For additional information regarding the liabilities, see Note 12 (Notes and Securities Payable), Note 13 (Warrants Payable), and Note 14 (Derivative Liabilities) in the 2021 Form 10-K.

The fair value of Legacy Clover's convertible securities was based on Level 3 inputs, which were unobservable and reflected management's best estimate of what market participants would use when pricing the asset or liability, including assumptions about risk. There was no fair value associated with convertible securities at March 31, 2022, due to the conversion of the securities to shares of the Company's common stock upon the completion of the Business Combination.
15


There were no changes in balances of Legacy Clover's Level 3 financial liabilities during the three months ended March 31, 2022. The changes in balances of Legacy Clover's Level 3 financial liabilities during the three months ended March 31, 2021, were as follows:
Convertible securitiesDerivative liabilitiesWarrants payableTotal
(in thousands)
Balance, December 31, 2020
$949,553 $44,810 $97,782 $1,092,145 
Issuances    
Settlements(949,553)(44,810)(97,782)(1,092,145)
Transfers in    
Transfers out    
Total realized losses (gains)    
Balance, March 31, 2021
$ $ $ $ 
In addition to the Level 3 financial liabilities in the table above, on September 25, 2020, Seek Insurance Services, Inc. (Seek), a field marketing organization and an indirect wholly-owned subsidiary of the Company, entered into a note purchase agreement with a third-party investor and issued a note (the "Seek Convertible Note") in the principal amount of $20.0 million, for which the carrying value is approximately the same as the fair value. For additional information, see Note 8 (Notes and Securities Payable). As of March 31, 2022, and December 31, 2021, both the carrying value, which includes accrued interest, and the fair value of the Seek Convertible Note were $22.4 million and $22.0 million, respectively, and these were considered Level 3 financial liabilities.
There were no transfers in or out of Level 3 financial assets or liabilities for the three months ended March 31, 2022 or 2021.
Warrants
Warrants were accounted for as liabilities in accordance with ASC 815-40 and are presented within warrants payable on the Condensed Consolidated Balance Sheet. The warrant liabilities were measured at fair value at inception and measured on a recurring basis, with changes in fair value presented within change in fair value of warrants payable in the Condensed Consolidated Statement of Operations and Comprehensive Loss. The Company determined that the public warrants assumed in connection with the Business Combination were classified within Level 1 of the fair value hierarchy as the fair value was equal to the publicly traded price of the public warrants, and the private placement warrants, also assumed in connection with the Business Combination, were classified within Level 2 of the fair value hierarchy as the fair value was estimated using the price of the public warrants. On July 22, 2021, the Company issued a press release stating that it would redeem all of its public and private placement warrants. In connection with the redemption, effective August 24, 2021, the public warrants were delisted and classified within Level 2 of the fair value hierarchy as the fair value of the public warrants was based on proportional changes in the price of the Company’s common stock. The end of the redemption period was September 9, 2021, at which time the Company redeemed all unexercised public and private placement warrants at a price of $0.10 per warrant. Following the redemption, no public or private placement warrants were outstanding. For additional information, see Note 5 (Fair Value Measurements) and Note 13 (Warrants Payable) in the 2021 Form 10-K.

5. Healthcare Receivables
Healthcare receivables include pharmaceutical rebates which are accrued as they are earned and estimated based on contracted rebate rates, eligible amounts submitted to the manufacturers by the Company's pharmacy manager, pharmacy utilization volume, and historical collection patterns. Also included in healthcare receivables are Medicare Part D settlement receivables, member premium receivables, and other CMS receivables. The Company reported $42.2 million and $48.0 million of healthcare receivables at March 31, 2022, and December 31, 2021, respectively.

6. Related Party Transactions
Related party agreements
The Company has various contracts with IJKG Opco LLC (d/b/a CarePoint Health - Bayonne Medical Center), Hudson Hospital Opco LLC (d/b/a CarePoint Health - Christ Hospital) and Hoboken University Medical Center Opco LLC (d/b/a CarePoint Health - Hoboken University Medical Center), which collectively do business as the CarePoint Health System (CarePoint Health). CarePoint Health is ultimately held and controlled by Vivek Garipalli, the Chief Executive Officer and a significant stockholder of the Company.
16


The Company contracts with CarePoint Health for the provision of inpatient and hospital-based outpatient services. Expenses and fees incurred related to these contracts, recorded in net medical claims incurred, were $2.6 million and $3.2 million for the three months ended March 31, 2022 and 2021, respectively. Additionally, $2.0 million and $2.3 million were payable to CarePoint Health as of March 31, 2022, and December 31, 2021, respectively.
The Company has contracted with Rogue Trading, LLC (Rogue), a marketing services provider. The Company's President, Andrew Toy, is related to the Chief Executive Officer of Rogue. There were no expenses and fees related to these contracts for the three months ended March 31, 2022. Expenses and fees related to these contracts were $0.2 million for the three months ended March 31, 2021.
The Company has a contract with Medical Records Exchange, LLC (d/b/a ChartFast) pursuant to which the Company receives administrative services related to medical records via ChartFast's electronic applications and web portal platform. ChartFast is ultimately owned and controlled by Mr. Garipalli. Expenses and fees incurred related to this agreement were $0.1 million and immaterial for the three months ended March 31, 2022 and 2021.
On July 2, 2021, the Company entered into a contract with Thyme Care, Inc. (Thyme Care), an oncology benefit management company, through which Thyme Care will provide concierge cancer coordination services to the Company's Insurance members in New Jersey and develop a provider network to help ensure member access to high-value oncology care. Mr. Garipalli is a member of Thyme Care’s board of directors. Expenses and fees incurred related to this agreement were $0.4 million for the three months ended March 31, 2022.

7. Unpaid Claims
Activity in the liability for unpaid claims, including claims adjustment expenses, for the three months ended March 31, 2022 and 2021, is summarized as follows:
Three Months Ended March 31,20222021
(in thousands)
Gross and net balance, beginning of period (1)
$136,137 $103,976 
Incurred related to:
Current year272,151 213,135 
Prior years(7,056)1,285 
Total incurred265,095 214,420 
Paid related to:
Current year164,034 130,447 
Prior years84,180 70,367 
Total paid248,214 200,814 
Gross and net balance, end of period (1)(2)
$153,018 $117,582 
(1)    Includes amounts due to related parties.
(2)    Differs from the total unpaid claims amount reported on the Condensed Consolidated Balance Sheets due to the fact the figure here excludes unpaid claims for the Company's Non-Insurance operations of $13.2 million as of March 31, 2022.
Unpaid Claims for Insurance Operations

Unpaid claims for Insurance operations were $153.0 million as of March 31, 2022. During the three months ended March 31, 2022, $84.2 million was paid for incurred claims attributable to insured events of prior years. A favorable development of $7.1 million was recognized during the three months ended March 31, 2022, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates as of December 31, 2021. An unfavorable development of $1.3 million was recognized during the three months ended March 31, 2021, resulting from the Company's actual experience with claims developing differently as compared to the Company's estimates as of December 31, 2020. Original estimates are increased or decreased, as additional information becomes known regarding individual claims. The ratio of current year medical claims paid as a percentage of current year net medical claims incurred was 60.3% for the three months ended March 31, 2022, and 61.2% for the three months ended March 31, 2021. This ratio serves as an indicator of claims processing speed, indicating that claims were processed at a slower rate during the three months ended March 31, 2022, than during the three months ended March 31, 2021.
17


The Company uses a variety of standard actuarial techniques to establish unpaid claims reserves. Management estimates are supported by the Company's actuarial an